A new model of experimental subretinal neovascularization in the rabbit.
Existing animal models of choroidal neovascularization (CNV) present several problems: they are hard to reproduce, they are inefficient, and the CNV created is not sustainable. The purpose of this study is to develop a highly efficient, reliable, sustainable rabbit model of CNV to facilitate the study of anti-angiogenic and anti-proliferative therapies for ocular diseases. Twenty-two pigmented rabbits were used in this study. Eleven rabbits received subretinal injections of either 10 microl of Matrigel with 500 ng of vascular endothelial growth factor (VEGF) or 20 microl of Matrigel with 750 ng of VEGF; eight rabbits received subretinal injections of either 10 or 20 microl of Matrigel only; three rabbits used as controls received subretinal injections of 20 microl phosphate-buffered saline (PBS) alone. Fundus photography, fluorescein angiography, optical coherence tomography, and histologic examinations were performed 1, 2, 4, and 9 weeks after injection. All experimental eyes showed angiographic leakage within this localized area 1 week after injection. The amount of leakage usually increased at weeks 2 and 4 and, in most cases, persisted at week 9. Control eyes demonstrated no leakage at any time point. Optical coherence tomography of treated eyes showed subretinal fluid and the presence of a lesion, possibly vascular or fibrotic, at the site of the leakage. Histologic analysis confirmed the presence of new subretinal blood vessels in the areas of Matrigel deposit. In conclusion, this novel method provides a highly reproducible, reliable, and sustainable rabbit model of experimental choroidal neovascularization. Such a model may prove useful for screening new anti-angiogenic therapies in a larger animal eye.
Doheny Retina Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo Street DEI 3622, Los Angeles, CA 90033-3699, USA. gqiu@doheny.org
Guanting
G
Qiu
Jay M
JM
Stewart
Srinivas
S
Sadda
Ricardo
R
Freda
Steven
S
Lee
Dilek
D
Guven
Eugene
E
de Juan
Signe E
SE
Varner
D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage; D002829:Choroid / Q000473:pathology; D020256:Choroidal Neovascularization / Q000473:pathology*; D003094:Collagen / Q000008:administration & dosage; D004195:Disease Models, Animal; D004338:Drug Combinations; D005451:Fluorescein Angiography / Q000379:methods; D007267:Injections; D007797:Laminin / Q000008:administration & dosage; D011509:Proteoglycans / Q000008:administration & dosage; D011817:Rabbits; D012160:Retina / Q000473:pathology; D012171:Retinal Vessels / Q000473:pathology; D041623:Tomography, Optical Coherence / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage
D001672:Biocompatible Materials; D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; D042461:Vascular Endothelial Growth Factor A; C059485:matrigel; D003094:Collagen